메뉴 건너뛰기
Revue de Medecine Interne
Volumn 27, Issue SUPPL. 1, 2006, Pages
Therapeutic goals in Gaucher disease
Author keywords

Enzyme replacement treatment
Indexed keywords

IMIGLUCERASE; ALGLUCERASE; MIGLUSTAT;
EID: 33646488206     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/S0248-8663(06)80009-3     Document Type: Article
Times cited : (8)
References (6)
  • 1
    • 0030030138 scopus 로고    scopus 로고
    • Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues
    • Xu Y.H., Ponce E., Sun Y., Leonova T., Bove K., Witte D., and Grabowski G.A. Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues. Pediatr Res 39 (1996) 313-322
    • (1996) Pediatr Res , vol.39 , pp. 313-322
    • Xu, Y.H.1    Ponce, E.2    Sun, Y.3    Leonova, T.4    Bove, K.5    Witte, D.6    Grabowski, G.A.7
  • 2
    • 0033134795 scopus 로고    scopus 로고
    • A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosi dase: implications for clinical efficacy in treatment of Gaucher disease
    • Friedman B., Vaddi K., Preston C., Mahon E., Cataldo J.R., and McPherson J.M. A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosi dase: implications for clinical efficacy in treatment of Gaucher disease. Blood 93 (1999) 2807-2816
    • (1999) Blood , vol.93 , pp. 2807-2816
    • Friedman, B.1    Vaddi, K.2    Preston, C.3    Mahon, E.4    Cataldo, J.R.5    McPherson, J.M.6
  • 3
    • 0037159549 scopus 로고    scopus 로고
    • Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry
    • Weinreb N.J., Charrow J., Andersson H.C., Kaplan P., Kolodny E.H., Mistry P., et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113 (2002) 112-119
    • (2002) Am J Med , vol.113 , pp. 112-119
    • Weinreb, N.J.1    Charrow, J.2    Andersson, H.C.3    Kaplan, P.4    Kolodny, E.H.5    Mistry, P.6
  • 4
    • 0034728914 scopus 로고    scopus 로고
    • Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
    • Cox T., Lachmann R., Hollak C., Aerts J., van Weely S., Hrebicek M., et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355 (2000) 1481-1485
    • (2000) Lancet , vol.355 , pp. 1481-1485
    • Cox, T.1    Lachmann, R.2    Hollak, C.3    Aerts, J.4    van Weely, S.5    Hrebicek, M.6
  • 5
    • 0037762566 scopus 로고    scopus 로고
    • Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease
    • Moyses C. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lend B Biol Sci 358 (2003) 955-960
    • (2003) Philos Trans R Soc Lend B Biol Sci , vol.358 , pp. 955-960
    • Moyses, C.1
  • 6
    • 20944439209 scopus 로고    scopus 로고
    • Individualization of long-term enzyme replacement therapy for Gaucher disease
    • International Collaborative Gaucher Group U.S. Regional Coordinators
    • Andersson H.C., Charrow J., Kaplan P., Mistry P., Pastores G.M., Prakesh-Cheng A., et al., International Collaborative Gaucher Group U.S. Regional Coordinators. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 7 (2005) 105-110
    • (2005) Genet Med , vol.7 , pp. 105-110
    • Andersson, H.C.1    Charrow, J.2    Kaplan, P.3    Mistry, P.4    Pastores, G.M.5    Prakesh-Cheng, A.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.